Cloning, Expression, Characterization and in silico studies of L-asparaginase from Vibrio sp. (GBPx3).

Sareh Sadat Mousavi Natanzi, Sedigheh Asad, Hossein Mahboudi, Solat Eslami
{"title":"Cloning, Expression, Characterization and in silico studies of L-asparaginase from Vibrio sp. (GBPx3).","authors":"Sareh Sadat Mousavi Natanzi, Sedigheh Asad, Hossein Mahboudi, Solat Eslami","doi":"10.1016/j.biochi.2025.03.003","DOIUrl":null,"url":null,"abstract":"<p><p>L-asparaginase is a critical therapeutic enzyme for treating acute lymphoblastic leukemia (ALL), a common childhood malignancy. In this study, the L-asparaginase coding sequence from halophilic Vibrio sp. (GBPx3) was cloned, expressed in Escherichia coli, and characterized. The enzyme exhibited a molecular weight of 39.2 kDa and demonstrated a K<sub>m</sub> of 4.517 mM, k<sub>cat</sub> of 2.88 1/s, and V<sub>max</sub> of 0.1055 μmol/min, reflecting high specificity for L-asparagine and minimal activity (0.4%) toward L-glutamine. Optimal activity was observed at physiological conditions (37°C, pH 7.5 and 125-150 mM NaCl), consistent with human serum osmolality. The half-life of the enzyme was 2.64 hours in human serum at 37°C that is longer than the half-life reported for E. coli L-asparaginase. Additionally, the enzyme had no toxic impact on human umbilical vein endothelial cells (HUVEC) and human erythrocytes. The recombinant L-asparaginase was predicted to be 29.3% helix, 35.6% turns, and 35.1% random by circular dichroism spectroscopy. AlphaFold predicted a 3D structure with promising validation scores. The molecular docking study showed that Thr14, Ser60, Thr91, and Asp92 are putative active site residues, with a negative binding energy of -4.5 kJ/mol for the substrate-enzyme interaction. The enzyme's low immunogenicity, high serum stability, and reduced glutaminase activity highlight its potential as a safer therapeutic alternative. Future experiments and protein engineering studies are needed to explore enzyme's in vivo efficacy and improve its clinical effectiveness.</p>","PeriodicalId":93898,"journal":{"name":"Biochimie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.biochi.2025.03.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

L-asparaginase is a critical therapeutic enzyme for treating acute lymphoblastic leukemia (ALL), a common childhood malignancy. In this study, the L-asparaginase coding sequence from halophilic Vibrio sp. (GBPx3) was cloned, expressed in Escherichia coli, and characterized. The enzyme exhibited a molecular weight of 39.2 kDa and demonstrated a Km of 4.517 mM, kcat of 2.88 1/s, and Vmax of 0.1055 μmol/min, reflecting high specificity for L-asparagine and minimal activity (0.4%) toward L-glutamine. Optimal activity was observed at physiological conditions (37°C, pH 7.5 and 125-150 mM NaCl), consistent with human serum osmolality. The half-life of the enzyme was 2.64 hours in human serum at 37°C that is longer than the half-life reported for E. coli L-asparaginase. Additionally, the enzyme had no toxic impact on human umbilical vein endothelial cells (HUVEC) and human erythrocytes. The recombinant L-asparaginase was predicted to be 29.3% helix, 35.6% turns, and 35.1% random by circular dichroism spectroscopy. AlphaFold predicted a 3D structure with promising validation scores. The molecular docking study showed that Thr14, Ser60, Thr91, and Asp92 are putative active site residues, with a negative binding energy of -4.5 kJ/mol for the substrate-enzyme interaction. The enzyme's low immunogenicity, high serum stability, and reduced glutaminase activity highlight its potential as a safer therapeutic alternative. Future experiments and protein engineering studies are needed to explore enzyme's in vivo efficacy and improve its clinical effectiveness.

求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信